The vaccine conjugates market is anticipated to reach USD 17.23 Billion by 2030 at 15.2% CAGR during the forecast period 2022-2030.Conjugate vaccines have helped to reduce Hib and meningitis in developed and developing nations. Experts say that conjugate vaccines are very effective in immunizing bacterial meningitis for children below 2 years. Conjugated vaccines for Hib have been increasingly used in several countries for covering three doses. Further, to this report, the increase in the investment by the major companies has been under the review period. The increase in the prevalence of infectious disease within children and also the rising range in the number of all awareness programs has been to promote the driving growth of the entire market analysis.
The market growth will be attributed to the high prevailing of infectious disease, improved efforts by the government and corporates for vaccine R & D. Since the focus on immunization has increased, capital investments have increased from the last few years.
In a number of nations, the use of conjugated Hib vaccines that provide three doses has increased. In addition to this report, the period under review also encompassed the increase in investment by significant companies. The increase in the prevalence of infectious diseases among children and the rise in the number of awareness programs have contributed to the expansion of the market research.
The growth of the market will be attributable to the prevalence of infectious diseases as well as increased government and corporate efforts in vaccine research and development. Since the emphasis on immunization has increased in recent years, capital expenditures have increased.
In the coming years, financial assistance and other forms of government assistance will aid in advancing the vaccine conjugates market's growth. This will contribute to the advancement of vaccine formulations and production, preventing the proliferation of infectious diseases. Pandemics and the rapid spread of disease will increase public and private interest in devising immunization programs. The increased demand for vaccination in recent years for the treatment of various infectious and chronic diseases will drive market growth for vaccine conjugates.
COVID- 19 Analysis
The focus on immunization has increased due to the rapid spread of the infection. Research is ongoing which is indicates that strong immune systems are required from childhood, which further helps the individuals in fighting infectious disease. It also observed that pandemic condition is not certain, hence the end cannot be determined, due to which vaccines doses might be increased in the upcoming months as a different variant of the viruses has been observed in nations. The need for vaccine conjugatesin the upcoming years will be coupled due to the improvisation of vaccination in varied countries of the world owing to the ongoing research in COVID-19.
A noteworthy landmark was achieved with the approval of Badan Pengawas Obat dan Makanan (BPOM), the national regulatory agency in Indonesia, granting Bio Farma a license to market its Bio-TCV® typhoid conjugate vaccine (TCV). This developmental TCV®, Vi polysaccharide-protein conjugated to diphtheria toxoid carrier protein (Vi-DT), is a product of IVI that was transferred to Bio Farma in 2014.
World Health Organization (WHO) recommended R21/Matrix-M as a new vaccine for malaria prevention among children earlier this month. This was later approved by the WHO Director-General during his biannual meeting held between the 25th and 29th of September when it came up before him for consideration following recommendations from the WHO Strategic Advisory Group of Experts on Immunization (SAGE) and Malaria Policy Advisory Group (MPAG). In addition, SAGE recommended other vaccines against dengue fever and meningitis, along with immunization schedules and products for COVID-19. At the same time, WHO made major immunization programmatic recommendations on Polio, IA2030, and recovery of the immunization programme.
Last June, the pneumococcal conjugate vaccine (PCV) was launched all over the state. The PCV was launched at KDS District Hospital by ZPC Leki Gombu and Jang ADC RD Thungon in Tawang. Another place where PCV was launched is Lungla CHC, led by Dr Tsering Penjor, while Mogto CO Dorjee Wangchu did so at Mogto Circle headquarters. A pledge to stop smoking and avoid any tobacco product use was taken on World No Tobacco Day by all employees, including doctors at KDS District Hospital.
August 2023: marked the start of a mass vaccination campaign against typhoid in the Arivonimamo and Antananarivo-Atsimondrano districts of Madagascar by the International Vaccine Institute (IVI) and Madagascar Institute for Vaccine Research (MIVR) at the University of Antananarivo. This vaccination campaign is part of the Typhoid Conjugate Vaccine Introduction in Madagascar (TyMA) project, which aims to assess the real-world effectiveness of Vi-CRM197 (trade name TYPHIBEV, made by Biologicals E Limited), a typhoid conjugate vaccine (TCV) pre-qualified by World Health Organization in a high burden setting as a step towards incorporating this vaccine into routine vaccination programs in Madagascar.
In the upcoming years, financial support and other types of government support will help in improving the development which will foster vaccine conjugates market growth. This will further help in advancing vaccine formulas and manufacturing, thereby preventing the spread of infectious diseases. The conditions like pandemics and rapid increase of disease will improve public and private focus for developing immunization programs. The demand for vaccination has improved from past years for treating several types of infectious and chronic diseases which will propel vaccine conjugates market growth.
During the forecast period, it is estimated that investments from both the public and private sectors will increase. Owing to the increasing need for vaccination for various diseases especially corona thus providing lucrative opportunities for vaccine conjugates market growth. Also, ongoing R&D will help in developing vaccines to combat coronavirus and its various versions which will foster vivid opportunities for enhancing vaccine conjugates market size.
The vaccine conjugates go through a complex manufacturing process which restricts profitability with an increased cost of production. In addition to this, vaccine conjugates market share will be challenged with negative perceptions regarding fraudulent activities and the manufacturing of fake vaccines. For example, a Chinese manufacturing company was found guilty due to the fabrication of its records in the production and distribution of vaccines.
The minimum control of Coronavirus disease can be done through vaccinations; hence the entire region will be covered as market areas. In many developing and underdeveloped regions, the route of rural areas is still not efficiently connected with main cities. This will impact the distribution of vaccines, hence indirectly impacting the vaccine conjugate market share. Also, several countries are engaged in the production and manufacturing of vaccines for promoting the growth of homegrown companies. Thereby, vaccine conjugates market growth in the global markets will be hindered. This restraint is further supported by international restrictions on import and export due to pandemics.
In addition to this, another situational factor that will restrict the market growth will include risks of shortage, worsening oligopoly conditions, uncertainty on futuristic initiatives, and others.
Cumulative Growth Analysis
From the year 2014, rapid growth within the vaccine conjugates market has been witnessed owing to increasing R&D in chronic disease and investments from various national and international agencies. During the forecast period, it is estimated that conjugated vaccines for adults will be increased which is further supported with regulatory approvals. Also, markets in Asian economies will provide high vaccine conjugates market growth.
Value Chain Growth
An increase in the number of vaccine conjugates growth has given a rise in the market. Hence, this has contributed to the entire overall impact on the market positively. Also, the growing initiatives by the government for the development and research will improve the value chain of the Vaccine Conjugates Market in the forthcoming years.
Additionally, the segments for vaccine conjugates market growth will include disease indication, pathogen, type, patient stage, and geography. The conjugate market and its entire market segmentation have been under the basis of the indication, type, and end-users. Thus, on all of this particular basis, the conjugate vaccine market has been segmented into adults and pediatrics. This claims the importance of the information gathered from WHO, European Society of Clinical Microbiology, U.S National Library of Medicines, and other sources.
Regional Analysis
The vaccine conjugates market size has been subdivided into North America, Europe, Asia Pacific, and the rest of the world. On this regional basis, the conjugate vaccine market has been segmented and America appears to be considered as the largest share of the market with favorable implications to the world market. Europe has been under the second-largest position in this globe and later has been followed by Asia-Pacific. Thus, in Europe, the availability of funds for research has been under the growing emphasis that prevents the increase of the prevalence of the disease. further, Asia-pacific has the fastest growth in the conjugate market and due to it, the developing countries have been emphasized with managing decisions. thus, the developing countries within this region manage to prevent the measures for treating them. mostly, India and China have been expecting to be in an emerging position that fastens the growth of the global market. Lastly, the Middle East & Africa happen to own the lowest share in the market due to the less availability of the medical facilities of the global conjugate vaccine market.
2018:Pfizer Inc. had received the designation in breakthrough therapy from FDA. The designation was received for 20 valent pneumococcal conjugate vaccines which will prevent pneumonia and other invasive diseases diagnosed in 18 years and above. In the year 2016, Pfizer Inc. had received approval from European Commission for its conjugated vaccine against IMD and others. It is expected that this market player will achieve the highest growth rate due to its consignment of supplying vaccines developed for pandemics throughout many regions of the world.
July 2023:According to a company press release from July 2023, Biosynth has acquired celares, a leader in the development and manufacture of conjugate vaccines and bioconjugate drugs, activated PEGs, and polymer-based drug delivery excipients. The acquisition will continue to enhance the area of conjugate vaccines and bioconjugate pharmaceuticals and expand Biosynth's capabilities at its Berlin, Germany, good manufacturing practice facilities.
July 2023:The World Health Organization (WHO) has prequalified MenFive, the first conjugate vaccine to protect against the five most prevalent causes of meningococcal meningitis in Africa, as of July 2023. MenFive protects against meningococcal serogroups A, C, W, Y, and X and is designed to eliminate annual meningitis outbreaks and epidemics in the African meningitis belt. It was developed through a 13-year collaboration between Serum Institute of India Pvt Ltd (SII) and PATH, with crucial funding from the UK government's Foreign, Commonwealth and Development Office.
August 2023:The International Vaccine Institute (IVI) and the Madagascar Institute for Vaccine Research (MIVR) at the University of Antanararivo have launched a mass vaccination campaign against typhoid in the Arivonimamo and Antananarivo-Atsimondrano districts of Madagascar.
Report Overview
This report mainly includes all the details and it tends to initialize the growth along with better efficiency of the market with particular management. It states that the driving factors have been interrupted due to the sudden covid 19 situations. The entire analysis is based upon the Covid 19 analysis, regional analysis, market overview, segmentation analysis, market dynamics and it mainly includes the challenges, opportunities, restraints, and drivers. Further, the competitive landscape and the other sections are presented. Hence, all of the information that has been collected is from the primary as well as the secondary sources.
By Geographically
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â 2030: USD 17.23 Billion |
| Â Â CAGR | Â Â 15.2% (2022-2030) |
| Â Â Base Year | Â Â 2021 |
| Â Â Forecast Period | Â Â 2022-2030 |
| Â Â Historical Data | Â Â 2020 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â By Type, Pathogen Type, Patient Stage, End-User |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â GlaxoSmithKline plc (U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Johnson & Johnson (U.S.), Medimmune, LLC (U.S.), Astellas Pharma Inc. (Japan), Serum Institute of India (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Fablife. (India), SutroVax Inc. (U.S), Sinovac Biotech Ltd. (China), and others. |
| Â Â Key Market Opportunities | Â Â The rising occurrence of diseases caused by microorganisms, increasing awareness about prevention of infectious diseases |
| Â Â Key Market Drivers | Â Â Increasing number of regulatory approvals to the vaccines are expected to drive the growth of the market |
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
